DUBLIN, IRELAND, July 30, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.63 per share. This represents a $0.06 increase in the dividend and the Company’s 20th consecutive year of dividend growth. The dividend is payable on September 26, 2025, to shareholders of record at the close of business on September 4, 2025. Additional information about the U.S. tax treatment of dividends, including requir ...

Group 1 - Steris is expected to report a year-over-year increase in earnings, with a consensus estimate of $2.32 per share, reflecting a +14.3% change, and revenues projected at $1.36 billion, up 6.2% from the previous year [3][12] - The earnings report is anticipated to be released on August 6, and the actual results will significantly influence the stock price, depending on whether they meet or exceed expectations [2][12] - The consensus EPS estimate has been revised 0.1% higher in the last 30 days, indicating a slight positive adjustment by analysts [4] Group 2 - The Earnings ESP for Steris is -3.24%, suggesting a bearish outlook from analysts, which complicates the prediction of an earnings beat [12] - Historically, Steris has beaten consensus EPS estimates three out of the last four quarters, with a recent surprise of +5.79% in the last reported quarter [13][14] - The Zacks Rank for Steris is currently 3 (Hold), which, combined with the negative Earnings ESP, makes it challenging to predict a positive earnings surprise [12][19] Group 3 - In the broader industry context, CVRx is expected to report a loss of $0.52 per share, indicating a +20% year-over-year change, with revenues projected at $13.46 million, up 14% [18] - CVRx's consensus EPS estimate has remained unchanged over the last 30 days, but it has an Earnings ESP of -0.65%, reflecting a lower Most Accurate Estimate [19]

DUBLIN, IRELAND, July 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2026 first quarter results at 9:00 a.m. ET on August 7, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after ...

Core Viewpoint - Steris (STE) has experienced significant selling pressure, declining 6% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory, with analysts expecting better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - STE's current RSI reading is 27.46, suggesting that the heavy selling pressure may be exhausting itself, indicating a potential trend reversal [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for STE have increased by 0.1% over the last 30 days, which usually correlates with price appreciation in the near term [7]. - STE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8].

Core Insights - STERIS plc's Healthcare segment is benefiting from strong market adoption of its infection prevention products and capital equipment, while the Applied Sterilization Technologies (AST) division is seeing solid growth due to increased service revenues [1][4][5] - The company has shown resilience in its stock performance, with a 6.2% increase over the past year, contrasting with a 12.2% decline in the industry [2] - STERIS has a market capitalization of $22.88 billion and an earnings yield of 4.4%, outperforming the industry's -2.9% [2] Healthcare Segment Performance - The Healthcare segment reported a 5% year-over-year revenue growth for the fourth quarter of fiscal 2025, driven by a 6% increase in consumable revenues and a 13% growth in service revenues [4] - The segment achieved a 6% constant currency organic revenue growth for the fiscal fourth quarter, with order growth exceeding 12% [4][8] - Margins improved due to increased volume, favorable pricing, and positive productivity, which offset labor inflation [4] AST Segment Growth - The AST division experienced a 9% year-over-year growth in the fiscal fourth quarter, supported by a 6% increase in service revenues [5] - The division is gaining traction with ethylene oxide sterilization, particularly among manufacturers of single-use sterile technologies for vaccines and biopharmaceuticals [5] - Constant currency organic revenues in the AST segment were in the high single digits, indicating strong demand from bioprocessing and stable global demand from MedTech customers [5] Financial Health - As of the fiscal fourth quarter of 2025, STERIS reduced its long-term debt by 38.5% to $1.92 billion from $3.12 billion a year earlier [6][9] - The company ended the fiscal third quarter with cash and cash equivalents of $171.7 million, exceeding its short-term debt of $125 million [6] - The total debt-to-capital ratio was 22.5%, down 33.2% year over year, indicating improved solvency [9] Challenges Facing the Company - The global macroeconomic environment has negatively impacted STERIS' financial operations, with rising healthcare costs and procurement challenges affecting production costs [10] - Customer consolidation due to competitive pressures and cost reduction measures has led to pricing pressure and potential customer loss for STERIS [11] Earnings Estimates - The Zacks Consensus Estimate for STERIS' fiscal 2026 earnings has increased by 0.9% to $10.11, with revenues projected at $5.83 billion, suggesting a 6.7% growth from fiscal 2024 [12]

Investor Presentation June 2025 Forward Looking Statements This presentation contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward- looking statements speak only as to the date the statemen ...

【全新修订】：2025年7月 【出版机构】：中智信投研究网 【内容部分有删减·详细可参中智信投研究网出版完整信息！】 【免费售后 服务一年，具体内容及订购流程欢迎咨询客服人员 】 报告目录 全球及中国无菌容器系统动向追踪及前景动态分析报告2025-2031年 8 全球主要生产商简介 8.1 Rebstock Instruments 8.1.1 Rebstock Instruments基本信息、无菌容器系统生产基地、销售区域、竞争对手及市场地位 1 美国关税政策演进与无菌容器系统产业冲击 1.1 无菌容器系统产品定义 1.2 政策核心解析 1.3 研究背景与意义 1.3.1 美国关税政策的调整对全球供应链的影响 1.3.2 中国无菌容器系统企业国际化的紧迫性：国内市场竞争饱和与全球化机遇并存 1.4 研究目标与方法 1.4.1 分析政策影响 1.4.2 总结企业应对策略、提出未来规划建议 2 行业影响评估 2.1 美国关税政策背景下，未来几年全球无菌容器系统行业规模趋势 2.1.1 乐观情形-全球无菌容器系统发展形式及未来趋势 2.1.2 保守情形-全球无菌容器系统发展形式及未来趋势 2.1.3 悲观情形-全球 ...

Company Overview - Steris shares have decreased by approximately 1.8% over the past month, underperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the key drivers affecting the stock [1] Earnings Estimates - Estimates for Steris have trended downward in the past month, indicating a negative outlook [2][4] - The stock currently holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the upcoming months [4] VGM Scores - Steris has an average Growth Score of C, a Momentum Score of C, and a Value Score of C, placing it in the middle 20% for investment strategies [3] Industry Performance - Steris is part of the Zacks Medical - Instruments industry, where Pacific Biosciences of California (PACB) has seen a gain of 11.3% over the past month [5] - Pacific Biosciences reported revenues of $37.15 million for the last quarter, reflecting a year-over-year decline of 4.3% [5] - The expected loss for Pacific Biosciences in the current quarter is $0.18 per share, with a year-over-year improvement of 10% [6]

Business Segments and Revenue - STERIS operates in three reportable business segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences, with the majority of revenues derived from healthcare and medical device customers[11]. - For the year ended March 31, 2025, no customer represented more than 10% of total revenues in any of the segments[17][21][26]. - As of March 31, 2025, the company reported a backlog of $452.9 million, with $369.2 million related to the Healthcare segment and $83.7 million to the Life Sciences segment, indicating an increase from $425.2 million in the previous year[49][50]. - Healthcare segment revenue increased to $12,341 million in fiscal 2025 from $11,419 million in fiscal 2024, representing an increase of 8.1%[78]. - Revenues increased by $320.8 million, or 6.2%, to $5,459.5 million for the year ended March 31, 2025, compared to $5,138.7 million for the year ended March 31, 2024[205]. Research and Development - STERIS invests significantly in research and development to discover and market innovative, cost-effective products and services[45]. - The company has 607 U.S. patents and 2,315 patents in other jurisdictions, with 90 U.S. patent applications and 289 applications pending[31]. Operational Performance and Costs - STERIS experienced a rise in supply chain and labor costs during fiscal 2023 and 2024, which moderated in fiscal 2025[29]. - The company applies Lean principles across its operations to enhance performance, agility, and value[34]. - The average number of employees during fiscal 2025 was approximately 18,000, with less than 11% represented by work councils or labor unions, indicating generally good employee relations[77]. - Total employees rose to 17,787 in fiscal 2025, up from 16,768 in fiscal 2024, reflecting a growth of 6.1%[78]. - Total employee costs increased to $1,850,544 thousand in fiscal 2025 from $1,718,164 thousand in fiscal 2024, marking a rise of 7.7%[86]. - The company maintained zero Class I recalls in fiscal 2025, 2024, or 2023, demonstrating strong compliance with safety standards[89]. Environmental and Sustainability Efforts - The company has made significant investments to comply with environmental laws and regulations, focusing on improving energy and water efficiency and reducing waste[69]. - The company tracks greenhouse gas emissions and reports direct and indirect energy use, participating in the Carbon Disclosure Project[70]. - The company has developed new products aimed at reducing environmental impact, such as ultra-concentrate cleaning chemistries that offer 10 times the uses per container[71]. - The company has established key performance indicators aligned with Sustainability Accounting Standards Board (SASB) Standards for Medical Equipment & Supplies, focusing on financial materiality in sustainability reporting[56]. - STERIS has three facilities accredited to ISO 14001 and ISO 45001 standards, reflecting commitment to environmental management[82]. Regulatory and Compliance Challenges - STERIS is subject to extensive governmental regulations, which require compliance and can significantly impact operations and costs[38][39]. - The company faces extensive regulatory requirements for product approvals, and delays in obtaining these could harm revenues and profitability[106]. - Compliance with international laws and regulations may be burdensome and expensive, impacting operational efficiency[103]. - Regulatory changes regarding greenhouse gas emissions and sustainability reporting may impose additional compliance costs and risks of non-compliance[138]. - The company's EO sterilization operations are at risk from regulatory actions that could significantly affect operational costs and demand for medical devices[141]. Financial Position and Debt - As of March 31, 2025, STERIS had approximately $2,043.7 million of outstanding indebtedness, including $1,350.0 million of Senior Public Notes, $674.2 million of Private Placement Senior Notes, and $34.8 million under the Revolving Credit Facility[153]. - The debt-to-total capital ratio was 23.6% at March 31, 2025, indicating a stable capital structure[209]. - The company expects to continue paying cash dividends for the foreseeable future, as determined by its Board of Directors[187]. Acquisitions and Growth Strategy - Acquisitions are a key part of STERIS's long-term growth strategy, alongside organic opportunities[45]. - The company completed several tuck-in acquisitions during fiscal 2025, with total aggregate consideration of approximately $54.1 million, enhancing its Healthcare and AST segments[201]. - The acquisition of assets from Becton, Dickinson and Company was valued at $539.8 million, financed through borrowings from the existing credit facility[203]. - The company plans to sell its Dental segment for total cash consideration of $787.5 million, with potential additional payments based on revenue targets in fiscal 2025[205]. Employee Relations and Engagement - Employee turnover rate was 16% in fiscal 2025, slightly up from 15% in fiscal 2024, with a goal to achieve a rate of 10% or less[85]. - 88% of employees participated in the pulse survey in fiscal 2025, indicating strong engagement levels[85]. Cybersecurity and Risk Management - The company has implemented a cybersecurity risk management program integrated into its enterprise risk management (ERM) framework, with no material cyberattacks reported in fiscal year 2025[178]. - The company maintains a comprehensive incident response policy for managing cybersecurity incidents, overseen by an Executive Cybersecurity Steering Committee[173]. - The company may face increased cybersecurity risks due to reliance on IT systems and remote work arrangements[149]. Market and Competitive Environment - The competitive environment is intensifying, with increased competition from new products and technologies in infection prevention and sterile processing[128]. - Consolidations among healthcare customers may lead to pricing pressures and potential loss of customers[130]. - Geopolitical instability may lead to supply chain disruptions, increased production costs, and reduced consumer demand, potentially adversely affecting the company's business[102]. Legal and Liability Risks - The company is exposed to product liability claims, which could result in substantial costs and distract management from core responsibilities[110]. - Future litigation related to EO operations may increase costs and divert management attention, potentially impacting financial results[144]. - STERIS agreed to pay up to approximately $48.2 million to resolve claims related to EO exposure in Illinois[143].

STERIS' (STE) new acquisitions and partnerships strengthen its product offerings. The stock carries a Zacks Rank #2 (Buy) currently.Factors Driving STERIS' GrowthSTERIS’ Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain that equipment, repair reusable procedural instruments and outsource instrument reprocessing services are gaining traction. For the fourth quart ...